Zanubrutinib

Generic Name
Zanubrutinib
Brand Names
Brukinsa
Drug Type
Small Molecule
Chemical Formula
C27H29N5O3
CAS Number
1691249-45-2
Unique Ingredient Identifier
AG9MHG098Z
Background

Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that pl...

Indication

Zanubrutinib is indicated for the treatment of:

Associated Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Refractory Marginal Zone Lymphoma, Relapsed Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenström's Macroglobulinemia (WM)
Associated Therapies
-

Epcoritamab, Zanubrutinib, and Rituximab (EZR) for R/R FL Relapsed or Refractory Follicular Lymphoma

First Posted Date
2024-08-21
Last Posted Date
2024-08-21
Lead Sponsor
Reid Merryman, MD
Target Recruit Count
24
Registration Number
NCT06563596
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-08-20
Last Posted Date
2024-08-20
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
36
Registration Number
NCT06563505
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

First Posted Date
2024-08-20
Last Posted Date
2024-12-04
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
55
Registration Number
NCT06561347
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

First Posted Date
2024-08-15
Last Posted Date
2024-08-15
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
36
Registration Number
NCT06554600
Locations
🇨🇳

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou, Zhejiang, China

Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

First Posted Date
2024-08-09
Last Posted Date
2024-08-09
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
30
Registration Number
NCT06547944
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China

Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma

First Posted Date
2024-07-16
Last Posted Date
2024-08-09
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
39
Registration Number
NCT06504199
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

🇨🇳

Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China

Not yet recruiting
Conditions
First Posted Date
2024-07-05
Last Posted Date
2024-07-05
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
490
Registration Number
NCT06489184
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma

First Posted Date
2024-06-25
Last Posted Date
2024-06-25
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
30
Registration Number
NCT06474481

Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma

First Posted Date
2024-06-24
Last Posted Date
2024-07-18
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
30
Registration Number
NCT06471738
Locations
🇨🇳

Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital, Beijing, China

Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

First Posted Date
2024-06-21
Last Posted Date
2024-06-21
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
20
Registration Number
NCT06468943
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Nanjing, China

© Copyright 2024. All Rights Reserved by MedPath